Sirukumab

Drug Profile

Sirukumab

Alternative Names: CNTO-136; PLIVENSIA™; Shirukumabu

Latest Information Update: 26 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Centocor
  • Developer Centocor; GlaxoSmithKline; Janssen Biotech
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Rheumatoid arthritis
  • Phase III Giant cell arteritis
  • Phase II Asthma; Lupus nephritis; Major depressive disorder
  • Preclinical Atherosclerosis

Most Recent Events

  • 22 Sep 2017 Janssen receives complete response letter from the FDA for sirukumab in Rheumatoid arthritis
  • 28 Aug 2017 GlaxoSmithKline withdraws phase IIa trial in asthma in USA and Spain, prior to enrolment (NCT02794519)
  • 02 Aug 2017 The US FDA Arthritis Advisory Committee did not recommend approval of sirukumab for Rheumatoid arthritis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top